The proposed bill aims to restore public trust in health messaging by ensuring that all communications related to Food and Drug Administration (FDA)-regulated products adhere strictly to the promotional guidelines set forth by the FDA. It highlights concerns regarding past public health campaigns during the COVID-19 pandemic, where various state and federal entities allegedly overstated the benefits of interventions, leading to a decline in public confidence. To address this, the bill mandates that the Washington State Department of Health, other executive branch actors, and local health departments can only promote FDA-regulated products in compliance with FDA labeling conditions, which includes providing accurate information and necessary disclaimers.

Additionally, the bill establishes internal review processes for compliance, requires immediate corrective actions in case of violations, and mandates annual reporting to the state auditor. It also stipulates that violations by employees of the executive branch or local health departments may result in disciplinary actions, including termination. The bill emphasizes the importance of maintaining integrity in public health communications to rebuild trust and ensure that the public receives accurate and reliable information regarding health interventions.